CORT Q1 Deep Dive: Early Lifyorli Launch and Endocrinology Momentum Offset Margin Pressures

Biopharma company Corcept Therapeutics (NASDAQ:CORT) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 4.9% year on year to $164.9 million. On the other hand, the company’s full-year revenue guidance of $1 billion at the midpoint came in 6.5% above analysts’ estimates. Its non-GAAP loss of $0.30 per share was significantly below analysts’ consensus estimates.

Is now the time to buy CORT? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Corcept’s first quarter results were met with a positive market reaction, despite the company missing Wall Street’s revenue and profitability expectations. Management attributed the performance to strong demand for Corcept’s medications, noting record new prescription activity and broadening prescriber engagement, especially in the hypercortisolism business. President of Endocrinology Sean Maduck emphasized, “We ended the first quarter with a record number of new prescriptions written from a record number of prescribers, which translated to an all-time high for the number of patients receiving our medications.” Management highlighted that these trends are not yet fully reflected in reported revenue due to first-quarter insurance reauthorization delays, the onboarding of a new specialty pharmacy vendor, and the ramp-up period for new patients.

Looking ahead, Corcept’s updated guidance is underpinned by the anticipated sustained growth in both its endocrinology and oncology franchises. Leadership expects expanded screening for hypercortisolism and increased adoption of Cushing’s syndrome treatments to drive revenue higher as recent clinical trial results gain awareness among physicians. CEO Joseph Belanoff stated, “Increased demand for medications that treat Cushing’s syndrome will propel our endocrinology business for years to come.” Early Lifyorli uptake and its inclusion in national cancer guidelines are expected to accelerate oncology revenues, while upcoming clinical milestones in other pipeline assets could further shape the company’s long-term trajectory.

Key Insights from Management’s Remarks

Management pointed to robust prescription growth and a fast start for Lifyorli as key drivers, while operational challenges and investment in launches weighed on margins.

• Prescription growth momentum: The endocrinology division saw a surge in new patient starts and prescriber engagement, with March and April setting records for new prescriptions. Management noted that new patient additions are expected to translate into higher revenue in future quarters as insurance coverage and dose titration progress.
• Insurance reauthorization impact: Revenue in the first quarter was temporarily suppressed due to insurance companies’ annual reauthorization procedures, a common challenge in rare disease markets. Free drug supply during these gaps ensured patient continuity but delayed revenue recognition.
• Specialty pharmacy transition: The company’s new specialty pharmacy vendor successfully onboarded thousands of patients, smoothing out disruptions from last year’s transition. Management cited ongoing efforts to clear a backlog in insurance prior authorizations, which is expected to benefit the topline as the year progresses.
• Lifyorli early launch execution: Corcept’s oncology division rapidly commercialized Lifyorli for platinum-resistant ovarian cancer just days after early FDA approval. Over 200 physicians have prescribed the drug within the first month, with broad adoption across community and academic practices. President Roberto Vieira highlighted that Lifyorli’s preferred status in the National Comprehensive Cancer Network guidelines supports payer access and prescriber uptake.
• Ongoing investment in launches: Significant spending on sales, marketing, and medical infrastructure to support new product launches and growing demand contributed to negative operating margins. Management described these investments as necessary to scale both the endocrinology and oncology franchises for expected long-term growth.

Drivers of Future Performance

Corcept’s outlook for the coming quarters hinges on expanding adoption of new therapies, successful commercialization, and execution across its clinical pipeline.

• Cushing’s syndrome growth: Management expects continued increases in screening and diagnosis rates for hypercortisolism, with the CATALYST and MOMENTUM studies driving heightened physician awareness and new patient identification. Expanded treatment guidelines are anticipated to fuel prescription growth.
• Oncology franchise ramp: The launch trajectory for Lifyorli is expected to accelerate, supported by its inclusion in cancer treatment guidelines and broad prescriber interest. Management anticipates that Lifyorli could become the market leader in platinum-resistant ovarian cancer, with further growth potential from ongoing and future trials in other tumor types.
• Pipeline milestones and risks: Upcoming clinical readouts—including relacorilant in Cushing’s syndrome and BELLA, MONARCH, and DAZALS trials in oncology, metabolic, and neurology indications—are poised to shape Corcept’s long-term outlook. However, management acknowledges that execution challenges, regulatory reviews, and market adoption rates remain critical uncertainties.

Catalysts in Upcoming Quarters

In the upcoming quarters, our team will closely track (1) prescription trends and payer uptake for Lifyorli as adoption broadens, (2) the impact of expanded hypercortisolism screening on Cushing’s syndrome therapy growth, and (3) key clinical trial milestones for relacorilant, dazucorilant, and miricorilant. Progress in resolving insurance and pharmacy onboarding challenges will also be important signposts for operational execution.

Corcept currently trades at $50.19, up from $46.52 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).

Our Favorite Stocks Right Now

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.